A portfolio of first-in-class and best-in-class products found thanks to Nanocyclix® technology

 

Selectivity and exceptional potency against kinases

Oncodesign’s current internal portfolio is based entirely on Nanocyclix® technology. These programs are highly innovative and cover first-in-class and best-in-class opportunities in several therapeutic areas. Discover our portfolio of R&D products Our activated EGFR PET tracer successfully obtained proof of concept in a phase I study. The program is now ready to move to a larger phase II/III validation study. The RIPK2 program identified ODS-101, which is expected to enter clinical trials in 2022, as well as fast-followers and a back-up chemical series. RIPK2 inhibition represents a first-in-class opportunity as an innate immune system modulator and has potential in chronic inflammatory bowel disease (IBD) and other inflammatory and autoimmune conditions.   LRRK2 is one of the few Parkinson’s disease targets with potential for disease modification. It is notoriously difficult to find appropriate inhibitors for this target. Our program, in partnership with Servier since 2019, is progressing toward IND.   MNK1/2 is a potential immuno-oncology target kinase involved in translational machinery. Our program is currently in the advanced phase of lead optimization.

kinases-nanocyclix

Target

Therapeutic indication

Nanocyclix® diversity

Qualification

Orientation

Components optimisation

Preclinical development

Phase I.

EGFR

PET radiotracer

RIPK2

Immunology

LRRK2

Under licence

Parkinson’s Disease

MNK1/2

Oncology

Development projects for your molecule?